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Abstract
A fact which favors the increase in morbidity and mortality of malaria cases in the world is 
the resistance to chemotherapeutic agents that the parasite presents. Therefore, it is neces-
sary to identify new potential targets specific to the parasite in order to be able to perform 
a rational planning. One target for the evaluation of potential antimalarial compounds 
is isoprenoid synthesis, which occurs via the 2-C-methyl-d-erythritol-4-phosphate path-
way in Plasmodium falciparum. Several intermediaries and final products of this pathway 
were identified in the parasite and lead us to the conclusion that it is different from the 
vertebrate host. In this chapter, we describe the effect of some monoterpenes and sesqui-
terpenes on Plasmodium falciparum and Plasmodium berghei as potential antimalarial drugs.
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1. Introduction
Malaria is one of the major threats to human health, affecting an estimated number of 216 
million peoples in 2016 all over the world, leading to 445,000 deaths, mainly in the African 
continent [1]. The human malaria is caused by six different species of the genus Plasmodium, 
which are P. falciparum, P. vivax, P. ovale, P. malariae, Plasmodium knowlesi and P. simium, where 
the last one is exclusive to the Brazilian Atlantic Forest [2].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Plasmodium was first described in 1880 by Laveran, who observed it in human erythrocytes. 
In human Plasmodium genus, the life cycle is very similar between species, being character-
ized by a sexual phase in vector Anopheles and an asexual phase in the human host that can be 
divided into liver phase and intraerythrocytic phase [3] (Figure 1).
The cycle begins with the injection of infective sporozoites of salivary glands of Anopheles into 
the human host bloodstream. Once there, the sporozoites make their way into the liver, where 
they infect hepatocytes to start the first massive replication, an asexual process, known as exo-
erythrocytic schizogony. After 9–16 days, those new-formed merozoites are then released into 
the bloodstream in hepatocyte-derived vesicles [4], called merosomes, to avoid its capture by 
Kupffer cell. This liver endures this phase differently across different species which can last 
an average of 6 days (P. falciparum), 10 days (P. vivax), or 15 days (P. ovale and P. malariae) [5].
In the bloodstream, the merosomes are then disrupted liberating the merozoites, each merozoite 
infecting a single red blood cell (RBC). The process of invasion is complex, relying on diverse 
cell machineries, which permit the parasite to attach, reorientate, and invade, forming the para-
sitophorous vacuole [6]. Once in the erythrocyte, the parasite starts its asexual division, passing 
through different stages. The early trophozoite, called “ring stage”, starts to develop, enlarging to 
a mature trophozoite that has a high metabolic index. In the late stage, multiple nuclear divisions 
Figure 1. Malaria parasite life cycle. Schematic life cycle of P. falciparum in the invertebrate (left) and vertebrate hosts 
(right). 1. Hepatocytes invasion and exoerythrocytic schizogony to merozoites formation. 2. Release of merosomes in 
the blood stream. 3. Intraerythrocytic phase. 4. Parasite differentiation to gametocytes which ones could be ingested by 
invertebrate host. 5. Sexual phase in the midgut of invertebrate host. 6. Migration of sporozoites into salivary glands. 7. 
Injection of sporozoites during the blood meal.
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are triggered without cytokinesis, forming schizonts. Each schizont holds an average of 32 mero-
zoites (10 merozoites in average for P. knowlesi [7]) that are unleashed upon the RBC lysis. The 
whole process can take about 36–48 h in P. falciparum, 48 h in P. vivax and can reach even 72 h in 
P. malariae, but in P. knowlesi the cycle is 24 h, which is one factor that leads to its high virulence 
in humans [8]. Cell lysis coincides with fever symptoms, a response of immune system to the 
liberation of hemozoin and other parasite products into the bloodstream [9].
Within the red blood cells, the parasite can follow another path of development, differentiat-
ing into gametocytes. During a blood meal in an infected individual, the Anopheles female 
ingests those gametocytes. In the female of the Anopheles mosquito the parasite undergoes a 
meiotic division. Inside the mosquito gut, the gametocytes mature to form male and female 
gametes. The gametes undergo fertilization, forming the zygote, which transforms into an 
ookinete. The ookinete then penetrates the midgut and installs itself developing into oocyst. 
Under multiple cellular divisions, thousands of sporozoites are formed, which migrate to the 
salivary glands of the mosquito, to get expelled with anticoagulant factor contained in saliva 
during the next blood meal, restarting the cycle [10] (Figure 1).
Although P. vivax is the most prevalent parasite in the world, P. falciparum is responsible 
for most cases of severe malaria, being the most prevalent malarial parasite in the African 
continent, which accounts for 80% of the global disease burden. The groups with higher risk 
of malaria disease includes pregnant women, patients with HIV/AIDS, infants and children 
under 5 years old, whereas P. falciparum is responsible for about 70% of the malaria-related 
deaths. Although a lot of efforts have been made aiming to eradicate malaria, the World 
Health Organization (WHO) strives to reduce the mortality rates and malaria cases in 90% up 
to the year of 2030 [11]. The acquired drug resistance of the parasite continues to be a struggle 
in the fight against the disease, which led to rising of malaria-related death.
The resistance to antimalarial drugs is due to the indiscriminate use of the drugs and its incor-
rect use in treatment of malaria cases, such as wrong dosage, drug quality problems, erroneous 
diagnosis, not sticking to treatment, and others. These are characterized as treatment failure but 
can lead to a strong selective pressure in parasites, resulting in drug resistance. In recent years, 
with the emergence of artemisinin derivatives, resistance has allowed the number of cases to 
grow fast, especially in East Asia. Artemisinin, a sesquiterpene lactone, and its derivatives were 
adopted in the early 2000s as a first-line treatment in combined therapy for P. falciparum [12]. 
Artemisinin and its derivate can clear early trophozoites (ring stage), but the drug has a short 
span in vertebrate organisms, making it necessary to combined it with other drugs. In countries 
where P. vivax is the main malaria transmitter, the first-line treatment remains using chloro-
quine and primaquine, although WHO suggests that changes must be made to artemisinin-
based combined therapy (ACT) when the rate of chloroquine resistance have reached more 
than 10%. Some strategies have been adapted to control malaria, such as vector control; insec-
ticide-treated bed nets, indoor residual spraying, preventive treatment for pregnant women, 
and rapid diagnosis and treatment of infected individuals [1, 12, 13]. But considering the fast 
acquirement of resistance by parasites and vectors to drugs and insecticides, respectively, the 
development of an effective vaccine turns out to be an important issue. However Plasmodium 
species, especially P. falciparum, has a highly variant antigen pool, responsible for the adhesion 
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of infected red blood cells (RBCs) to small vessels, which causes aggregation that leads to severe 
stage of the disease, making difficult advances in this area of interest [9]. The pathogenesis of 
P. falciparum relies on a complex interaction of RBC alterations, microcirculatory anomalies, 
and immune response. The infected RBCs start to agglomerate in small vessels by action of 
adhesins expressed by the parasite on the surface of infected RBCs. Those adhesins are capable 
of interacting with endothelial cells of small vessels, to avoid the clearance of infected RBCs by 
the spleen, leading to a sequestration in diverse organs, such as brain, lungs, and placenta. This, 
together with other factors, causes the severe forms of malaria [9].
The increasing resistance of the parasite to practically all current medications, such as arte-
misinin in five countries in Asia, Southeast Asia and probably South America [1], calls for 
the use of combination drug therapy, as well as for the identification of new targets [12, 13]. 
Targets targeting the parasite for the development of new therapies for the treatment of 
malaria encompass both cellular functions, such as detoxification of heme or ferriprotopor-
phyrin IX (Fe (III) PPIX), and folate metabolism, already explored for drugs established as 
antimalarial, as well as other metabolic pathways, such as fatty acid synthesis, and isoprenoid 
biosynthesis, both of which are found in the apicoplast [14].
The apicoplast, an organelle originating from a secondary endosymbiotic origin of red algae, 
has lost its photosynthetic function in the course of evolution [15], and speculations have 
demonstrated its importance in the formation of essential components incorporated into the 
membrane of the parasitophorous vacuole [16]. Recently, it has been shown that isoprenoid bio-
synthesis is not only essential for the parasite but, in fact, is the only function of the apicoplast 
during blood stage growth [17] and sexual forms [18]. Parasites that lacked apicoplast can be 
chemically rescued by addition of isopentenyl pyrophosphate (IPP) to the growth media [17].
2. Isoprenoids in Plasmodium spp
All isoprenoids are derived from a common precursor, IPP and its dimethylallyl pyrophos-
phate isomer (DMAPP) [19] (Figure 2). The identification and characterization of farnesyl 
pyrophosphate (FPP) in P. falciparum [20], as well as the presence of proteins covalently modi-
fied by isoprenoids [21, 22] and dolichols [23], were the first evidence for the study of isopren-
oid biosynthesis in Plasmodium. In the last decade, there has been a broad characterization of 
isoprenoid biosynthesis products in the parasite [22–27] resulting from the alternative route 
2-C-methyl-d-erythritol-4-phosphate (MEP) [28, 29] (Figure 2). The essential and important step 
in the metabolism of the biosynthesis of all isoprenoids is the elongation of the isoprene chain by 
enzymes called prenyltransferases. These enzymes are classified according to the chain length 
of the final product and the stereochemistry of the double bond formed by condensations, with 
FPPS (farnesyl pyrophosphate synthase) and GGPPS (geranylgeranyl pyrophosphate synthase) 
being the most studied prenyltransferases [30]. FPPS catalyzes the condensation of IPP with 
DMAPP and geranyl pyrophosphate (GPP) to form the 15-carbon isoprenoid compound, farne-
syl pyrophosphate (FPP). FPP is the substrate that catalyzes the first step in the biosynthesis of 
ubiquinone, carotenoids, dolichols, and protein prenylation. FPP can also be condensed with an 
additional molecule of IPP by the enzyme GGPPS to form the 20-carbon isoprenoid, geranyl-
geranyl pyrophosphate (GGPP), also essential in protein isoprenylation [30] (Figure 2).
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For several decades, the mevalonate pathway, present in animals and plants, was considered 
the only route for synthesis of the isoprene units in isoprenoid biosynthesis. The existence of 
a second pathway for the biosynthesis of isoprene units was discovered in 1988 by Flesch and 
Rohmer when they were studying the hopanoids biosynthesis (pentacyclic triterpenic steroids) 
in bacteria [31]. Originally called the Rohmer’s pathway or mevalonate-independent pathway, 
its name was changed after the identification of the first step in the pathway (pyruvate/glycer-
aldehyde-3-phosphate GAP pathway) or the first intermediate, 1-deoxy-d-phosphate (DOXP 
pathway). However, the most accepted name is MEP [32], since this compound is the first 
exclusive pathway precursor. One particularly intriguing target from the MEP pathway is 
1-deoxy-d-xylulose-5-phosphate synthase (DXS). DXS catalyzes the first and rate-determining 
step of MEP and the condensation of pyruvate and d-glyceraldehyde-3-phosphate to 1-deoxy-
d-xylulose-5-phosphate (DXP) and CO
2
, this reaction being the first and rate-determining step 
of MEP [33]. The reactions catalyzed by DXS and DXR (1-deoxy-d-xylulose-5-phosphate reduc-
toisomerase) practically share the full control of the flux through MEP pathway. It was shown 
Figure 2. MEP pathway and final products in P. falciparum. In the left box, the MEP pathway to the formation 
of isoprenic units (IPP and DMAPP). In the right, final isoprenic products biosynthetized by P. falciparum. The 
circles are representing inhibitors tested against the parasite and the gray circles correspond to terpenes which 
its inhibitory effect on final isoprenic products biosynthesis was demonstrated. Abbreviations: Precursors: 
GAP, glyceraldehyde 3-phosphate; DOXP, 1-deoxy-d-xylulose 5-phosphate; MEP, 2C-methyl-d-erythritol 
4-phosphate; CDP-ME, 4-(cytidine-5′-diphospho)-2C-methyl-d-erythritol; CDP-MEP, 4-(cytidine-5′-diphospho)-
2C-methyl-d-erythritol 2-phosphate; MEcPP, 2C-methyl-d-erythritol 2,4-cyclodiphosphate; HMBPP, 1-hydroxy-
2-methyl-2-(E)-butenyl 4-diphosphate; IPP, isopentenyl pyrophosphate; DMAPP, dimethylallyl pyrophosphate; 
GPP, geranyl pyrophosphate; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate. Enzymes: 
DXS, 1-deoxy-d-xylulose 5-phosphate synthase; DXR, 1-deoxy-d-xylulose 5-phosphate reductoisomerase; MCT, 
2C-methyl-d-erythritol 4-phosphate cytidine transferase; CMK, 4-(cytidine-5′-diphosph)-2C-methyl-d-erythritol 
kinase; MCS, 2C-methyl-d-erythritol 2,4-cyclodiphosphate synthase; GcpE, hydromethylbutenyl pyrophosphate 
synthase; Lyt B, hydromethylbutenyl pyrophosphate reductase; IPP isomerase, isopentenyl pyrophosphate 
isomerase. Inhibitors: FTS, s-farnesylthiosalicylic acid; POH, perillyl alcohol.
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that reducing the flux through the pathway by inhibiting enzymes (DXS & DXR inhibition) is 
an important mechanism of action of some drugs leading to killing of the malarial parasite [34].
Fosmidomycin is a natural product antibiotic with activity against a number of important 
pathogens (Figure 2). It is a phosphoric acid that is a substrate mimic and direct inhibitor of 
the first dedicated MEP pathway enzyme, in which DXP is converted to MEP by DXR (also 
called IspC) [35, 36]. The use of fosmidomycin as a single-drug treatment for P. falciparum 
malaria has been hampered by low bioavailability, recrudescent, and rapid clearance from 
the parasite, although the compound has been used more successfully in combination with 
clindamycin [37]. Many efforts, with great results, have been made to improve the efficacy of 
fosmidomycin as modifications to the phosphonate group, extensions to the hydroxamic acid 
group [38, 39], and substitution of the α-position [40, 41] or, more recently, β-position [42]. 
The inhibition of downstream enzyme IspD (2-C-methyl-d-erythritol 4-phosphate cytidylyl-
transferase) which catalyzes the cytidylation of MEP to cytidine diphosphate methylerythri-
tol (CDP-ME) is also metabolically apparent in fosmidomycin-treated cells. Although IspD 
homologs are not directly inhibited by fosmidomycin in vitro, this enzyme has been shown as 
a promising target in isoprenoid pathway for some new antimalarial drugs studied [43, 44].
The first evidence for the study of isoprenoid biosynthesis in Plasmodium were the identifica-
tion and characterization of farnesyl pyrophosphate (FPP) [45], dolichols [23], and prenylated 
proteins in P. falciparum [21, 22]. Other products were functionally characterized, shown to be 
essential for the survival of the parasite, such as vitamin K2 (menaquinone-4) [24] and vitamin 
E (tocopherol) [25], for example. It was demonstrated that the vitamin K2 biosynthesized by 
the parasite acts as electron transporter in the respiratory chain in microaerophilic conditions 
and that this biosynthesis can be inhibited treating parasite culture with RO 48-8071, a spe-
cific inhibitor of manequinone-4 biosynthesis [24]. The biosynthesis of tocopherol (vitamin E) 
was characterized in the parasite and has been shown essential for antioxidant that protects 
against environmental stress, including maintaining ROS levels [46]. The parasite lives in a 
pro-oxidant environment that contains oxygen and iron and therefore have evolved extensive 
detoxifying and protective mechanisms, which both limit the production of and potential 
damage by ROS [27, 46]. Further, tocopherol has been showing excellent results in antimalarial 
drug studies, presented excellent results with usnic acid, a drug that inhibits hydroxyphenyl-
pyruvate dioxygenase, the enzyme that catalyzes the conversion of p-hydroxyphenylpyruvic 
acid to homogentisic acid, a precursor of vitamin E biosynthesis [27] (Figure 2).
The enzymes are important tool for study the parasite physiology and an important target 
for antimalarial drugs, due to its specificity. The essential step in all isoprenoids biosynthesis 
is the elongation of the isoprene chain by enzymes called prenyltransferases. These enzymes 
are classified according to the chain length of the final product and the stereochemistry of 
the double bond formed by condensations [47]. The most studied of these prenyltransferases 
has been FPPS and GGPPS in P. falciparum [20]. The gene coding for FPPS and GGPPS have 
already been identified and characterized in several species such as Saccharomyces cerevisiae 
[48], Trypanosoma cruzi [49], T. brucei [50], Toxoplasma gondii [51], P. vivax [52] and P. falciparum 
[20]. Both P. falciparum and T. gondii enzymes are bifunctional (FPPS/GGPPS), being able to cat-
alyze the biosynthesis of the isoprene compounds FPP and GGPP [20, 51], the main precursors 
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of all secondary products from isoprenoids pathways. Transcriptional analyses of the FPPS/
GGPPS gene have shown a high variability in alternative splicing of this P. falciparum gene [53]. 
It has been proven that the importance of this enzyme for the MEP pathway, due to the com-
plexity of the gene regulation, is necessary for the formation of the main precursors. Therefore, 
FPPS/GGPPS is a potential and promising target for new antimalarial drugs.
Risedronate, a bisphosphonate containing nitrogen (N-BP), showed potent activity against the 
blood phases of P. falciparum “in vitro” which inhibits FPPS/GGPPS activity by competitive 
inhibitor toward GPP and FPP [20] (Figure 2). Bisphosphonates are inhibitors of bone resorp-
tion and are in clinical use for the treatment and prevention of osteoporosis [54]. The activity 
of the risedronate was confirmed because only farnesyl-PP and geranylgeranyl-PP restored 
the growth intraerythrocytic stages of P. falciparum, after treatment with risedronate [55]. This 
drug also showed a significant inhibitory effect against murine blood stage malaria, without 
showing toxicity effects to the animals [55] and showed great results in synergism experi-
ments with other drugs in P. falciparum [56]. Also, crystallography assays of the P. vivax GGPP 
enzyme inferred that GGPP could be a major target for the lipophilic bisphosphonates [57].
Many studies of novel antimalarial drugs have been performed using enzymes as the primary 
target of action [58–60], although in isoprenoid biosynthesis of P. falciparum, few enzymes 
are still known and studied. The enzyme OPP/PSY (octaprenyl pyrophosphate synthase/phy-
toene synthase) was characterized in the parasite as a bifunctional [25, 61] responsible for 
form two important secondary products of the isoprenoid biosynthesis— carotenoids [25], 
important for antioxidant protection, and ubiquinone [24], essential for electron transfer in 
respiratory chain among other functions. Squalestatin, a carboxylic acid inhibitor of squalene 
synthase, the enzyme responsible for the first step of sterol biosynthesis, presented promis-
ing results as an antimalarial drug, specifically inhibiting OPP/PSY [62]. This results have 
proven then that the first carotenoid phytoene is essential for parasite development during 
the intraerythrocytic cycle [62], probably due its antioxidant protection function [25]. Also, 
through studies in silico characterized the secondary and tertiary structures of this enzyme, 
OPPS/PSY presented an unconserved unique loop in P. falciparum then be exploited for struc-
ture based drug designing against malaria parasite [63].
Since it was shown that the MEP pathway provides IPP precursors for the biosynthesis of 
higher isoprenic compounds, one of the strategies to identify secondary products of the MEP 
pathway was the metabolic labeling using a radioactive precursor and a posterior analysis by 
an appropriate method. In this context, it was identified in P. falciparum prenylated proteins 
[22], dolichols [23], ubiquinones [24], carotenoids [25], vitamin K2 [26], and vitamin E [27].
Different types of terpenes that exert antifungal, antibacterial, and antimalarial activity can be 
easily found in literature [19, 64, 65]. However, not all authors described a clear explanation 
about their mechanism of action. Recently, Silva et al. [66] listed 114 terpenes and their semi-
synthetic derivate with antimalarial activity, but only three have their mechanism of action 
elucidated. For several years, studies have been made of the large diversity of prenylated 
compounds biosynthesized by P. falciparum. That is why some research groups investigate the 
possibility of developing new antimalarial drugs that could interfere with the biosynthesis of 
isoprenoid compounds [19]. This interference in biosynthesis of isoprenoid compounds could 
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be produced by inhibiting the enzymes as isoprenyl diphosphate synthases and isoprenyl 
transferases. Thus, research in the area can benefit from obtaining better knowledge about the 
antimalarial activity of natural terpenes. Due to their structural similarity, it was suggested 
that terpenes might interfere with the parasite’s polyisoprenoid biosynthesis through inhibi-
tion of the isoprenyl diphosphate synthases which condense molecules of IPP among other 
isoprenic substrates to form isoprene chains [67]. Terpenes could also establish a competition 
with several enzymes which use isoprenic compounds as substrates. In fact, several terpenes, 
such as farnesol or linalool, have already demonstrated a capacity to inhibit at least one point 
of isoprenoid biosynthesis including isoprenic chain of ubiquinone and dolichol biosynthesis 
and protein isoprenylation [67]. These results suggest a widespread inhibitory action. Studies 
on antimalarial activity, drug combination, and mechanisms of action of different compounds 
are commonly performed in vitro (Figure 2).
It is known that IPP, FPP, and GGPP are substrates of the enzymes prenyltransferases involved 
in the biosynthesis of dolichol, the isoprenic side chain of ubiquinones, and the isoprenic chains 
attached to proteins, among other plasmodia prenylated compounds [68]. In order to deter-
mine if different drugs produce biosynthesis inhibitory effects on specific isoprenic compounds, 
treated cultures (using drugs concentration under the IC50 value), or untreated cultures can be radiolabeled by isoprenic precursors such as [1-(n)-3H]geranylgeranyl pyrophosphate triammo-
nium salt ([3H]GGPP), 1-(n)-3H]farnesyl pyrophosphate triammonium salt ([3H]FPP), or [1-14C]
isopentenyl pyrophosphate triammonium salt ([14C]IPP). Using these precursors, it is possible to 
label most isoprenic compounds without performing prenyl diphosphate pool substrate deple-
tion, as it is necessary in other cell systems [69]. This fact suggests that the Plasmodium may have 
a different kind of isoprenic precursor uptake from the extracellular medium in comparison to 
other organisms [24, 67, 69]. After purifying infected red blood cells containing parasites at dif-
ferent stages, prenylated compounds can be isolated by diverse methods, once their radioactiv-
ity incorporation is evaluated [19]. For apolar compounds, such as dolichol and ubiquinones, 
the apolar extracts are commonly obtained and chromatographed by different TLC or HPLC 
methods, while isoprenylated proteins can easily be isolated in a polyacrylamide electrophore-
sis gel. Specific proteins such as Ras or Rap proteins can be easily immunoprecipitated [67, 70].
Prenylated proteins are post-translational modified by farnesyl transferase and geranylgeranyl 
transferase by attaching isoprenic chains to C-terminal cysteine groups. Protein prenylation 
had already been characterized in several parasites such as Giardia lamblia, [71] Trypanosoma 
brucei [72] and Schistosoma mansoni [73]. P. falciparum expresses different classes of lipidic-mem-
brane-associated prenylated proteins such as GTPases Ras, Rho, and Rab including endosomal 
vesicles Rab7 protein [74] farnesylated PfPRL tyrosine phosphatase, SNARE protein Ykt6.1 
[75, 76], and some putative plasmodial isoprenylated proteins such as Rab2 and Rab11a [77]. 
In fact, proteins of 21 to 24 kDa and 50 kDa are identified using specific prenylated protein 
antibodies [22, 67, 78]. Some terpenes and prenyltransferase inhibitors have already shown 
interesting anti-cancer and anti-plasmodial activities [21, 79]. Limonene, linalool, and perillyl 
alcohol (POH) are some examples of these antineoplastic and antimalarial activities, and the 
mechanisms of action of most of them seem to be related to protein isoprenylation interfer-
ences [67, 80–82]. Several terpenes and protein isoprenylation inhibitors were studied for its 
antimalarial activity. Limonene, nerolidol, farnesol, perillyl alcohol, linalool and an terpene 
modified as s-farnesylthiosalicylic acid (FTS) are just a few examples of compounds tested in 
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P. falciparum and for the IC50 value in 3D7 P. falciparum isolate was calculated [67, 82]. All these 
compounds have demonstrated to produce a dose–response inhibition. The lowest IC50 values 
were found for nerolidol (IC50  ̴760 nM), perillyl alcohol (IC50  ̴489 μM), FTS (IC50  ̴14 μM) and 
farnesol (IC50  ̴64 μM), whereas limonene and linalool showed IC50 values in the millimolar 
scale [67, 82]. All this compounds showed effects on protein isoprenylation which vary in 
function of the parasitic stage and the given isoprenic radiolabeled precursor. Different drug 
effects in function of the parasitic stage and the given isoprenic radiolabeled precursor allow 
us to understand compound mechanism of action at the different intraerythrocytic stages of 
the parasite. Treatments on protein isoprenylation seem to be specific, since there was no sig-
nificant effect on L-[35S] methionine-labeled proteins [22, 67].
Anti-p21ras or anti-p21rap antibodies were used for immunoprecipitation with [3H]FPP or 
[3H]GGPP labeled proteins of untreated and treated parasites at different stages. Results indi-
cate that schizont p21rap radioactive incorporation is reduced after treatment with nerolidol, 
farnesol, linalool, limonene, and FTS. Farnesol inhibits isoprenylation of Ras and Rap proteins 
in all plasmodium intraerythrocytic stages whereas linalool inhibits Ras isoprenylation in ring 
and schizont stages. Also in the schizont stages, this effect on Ras proteins was observed as 
well as after FTS and limonene treatments. At ring stages, the limonene reduced the radioac-
tive incorporation into Rap and Ras proteins, and linalool reduced incorporation into 21 kDa 
band. In trophozoite stages, these effects in Rap radioactive incorporation were observed after 
limonene and nerolidol treatments [67]. FTS is a prenylated compound that also restrains the 
development of some tumors by inhibiting specifically Ras post-translational modifications 
[83]. As mentioned, the inhibition of Ras post-translational modifications in schizont stage 
and the hindrance of the parasite at this stage were also demonstrated for P. falciparum.
Carotenoids, dolichol, and coenzyme Q are examples of prenylated compounds biosynthe-
sized by P. falciparum isolated by diverse methods. Coenzyme Q has a role in mitochondrial 
respiration, in pyrimidine biosynthesis, and in preventing membrane lipoperoxidation, 
among other functions [84]. Carotenoids are believed to avoid oxidative stress; and dolichol 
and its phosphorylated derivatives can participate in protein prenylation [85] or act as lipids’ 
carriers, being used for several glycoconjugates [86] including N-linked glycoproteins. Those 
play an important role in the parasite’s intraerythrocytic stages differentiation [87]. The P. 
falciparum bifunctional enzyme OPPS/PSY is involved in the biosynthesis of carotenoids and 
isoprenic side chains attached to benzoquinone rings derived from p-hydroxybenzoic acid. 
The parasite is able to synthesize several carotenoids and at least two homologs of coenzyme 
Q (Q8 and Q9) that differ on the isoprenic units of the lateral chain [24, 25, 61]. Some authors suggested that the homologs might act against different kinds of oxidative stress conditions 
[24]. Several terpenes also demonstrated effects on dolichol and ubiquinone biosynthesis in 
different organisms. In hepatoma and Neuro2A cells, the monoterpenes limonene and linalool 
interfered in the biosynthesis of dolichol and the isoprenic side chains of benzoquinones [81]. 
Similarly, in P. falciparum, both monoterpenes and also farnesol and nerolidol interfered in 
the biosynthesis of dolichol and ubiquinones when the parasite was [14C]IPP labeled. Only the 
monoterpenes limonene and linalool interfered in geraniol and farnesol radioactive incorpo-
ration. That is why some authors suggested that limonene and linalool could be interfering in 
the condensation between IPP and DMAPP, while farnesol or nerolidol could be interfering in 
the isoprenic chains’ elongation [67]. In order to demonstrate terpenes, specifically effects on 
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P. falciparum isoprenoid-related enzymes, nerolidol was used to inhibit the OPPS/PSY activity 
using [3H]FPP and [14C]IPP as substrates. OPPS/PSY activity was competitively inhibited by 
nerolidol (K
i
 ̴ 15 nM) [61].
As we have seen, some MEP pathway and isoprenoid pathway inhibitors show good antima-
larial activity and produce important metabolic alterations in P. falciparum. Different authors 
asked if using terpenes individually or in combination with other drugs could be a good 
strategy to treat malaria. It is well established that fosmidomycin and clindamycin, when 
combined, produce a synergistic activity in vitro and in vivo [88], and several drugs which 
act at different points of the MEP/isoprenoid showed supra-additive in vitro effects when 
combined [56]. These kinds of drug combination studies are useful for a better understanding 
of the interactions between the different intermediates of the MEP and isoprenoid pathways 
and to evaluate its antimalarial potential. Fosmidomycin, risedronate, nerolidol and squales-
tatin (supposed to be a phytoene synthase inhibitor) are drugs which are believed to act in 
different cellular compartments, and all of them seem to inhibit at least one point related to 
isoprenoid metabolism [56]. Except nerolidol-risedronate, most binary combinations between 
fosmidomycin, risedronate, nerolidol and squalestatin showed a supra-additive effect [56]. 
Probably it is because they target different enzymes in the same biosynthetic pathway. On the 
other hand, nerolidol and risedronate when combined showed a sub-additive effect. It was 
suggested that this fact could be explained because both compounds affect the same target of 
isoprenoid pathways [56]. Nerolidol affects the synthesis of several isoprenoid compounds, 
including protein isoprenylation as well as risedronate [55, 67].
Due to the terpenes effectiveness to inhibit the P. falciparum growth in vitro, several studies 
have been focused on studying these effects on experimental models of malaria by P. berghei 
infection. Nerolidol for example, being administered on Balb/c mice at a dose 2000 mg/kg/
day by oral and intranasal via, had an inhibitory effect on the P. berghei ANKA growth, since 
the parasitemia were reduced and the survival rates were increased significantly with the 
nerolidol treatment [89]. Also, some derivatives of 4-nerolidylcatechol, at oral doses of 50 mg/
kg/day, had suppressed P. berghei NK65 in infected BALB/c mice by 44%, showing marked 
improvement over the parasite’s growth [90].
On the other hand, some metabolites derived from limonene, such as perillyl alcohol, have 
also been shown to be effective against the severe conditions development caused by P. ber­
ghei infection. C57BL/6 mice infected with P. berghei ANKA and treated with 500 mg/kg/day 
intranasal via had a significant increase in survival rates, showing a preventive effect against 
the experimental cerebral malaria development [82].
Furthermore, plant extracts that contain several terpenes have also been tested on experimen-
tal models. The antimalarial activity of ethanolic bark extract of A. lebbeck was determined. 
Phytochemical screening revealed the presence of alkaloids, flavonoids, phenols, saponins, 
terpenes, and phytosterols [91].
Limonoids isolated from the residual seed biomass from Carapa guianensis were tested against 
P. berghei and 6α-acetoxy-gedunin was more active than 7-deacetoxy-7-oxogedunin. At oral 
doses of 50 and 100 mg/kg/day, 6α-acetoxy-gedunin suppressed parasitemia versus untreated 
controls by 40 and 66%, respectively, evidencing a clear dose response [92].
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In other studies, methanol extracts of Carpesium rosulatum were found to have potential antima-
larial activity in vivo when tested against P. berghei in mice. A dose of 2, 5, 10 mg/kg/day exhib-
ited a significant blood schizonticidal activity in four-day early infection with a significant 
mean survival time comparable to that of the standard drug, chloroquine (5 mg/kg/day) [93].
Some others triterpenes isolated from the African medicinal plant, Momordica balsamina L. 
such as, balsaminoside B, karavilagenin C, and the karavoates B and D were synthesized by 
diacylation from these extracted terpenes. Derivatives exhibited sub-micromolar IC50 in vitro 
against P. falciparum strains and exhibited greater in vivo antimalarial activity. Orally and 
subcutaneously administered karavoate B exhibited the greatest in vivo antimalarial activity 
(55.2–58.1% maximal suppression of parasitemia at doses of 50 mg/kg/day) [94].
3. Conclusion
Plasmodium spp. has an organelle, the apicoplast, which is essential for the development of the 
parasite because it is linked to two metabolic pathways, one of which is the isoprenoid biosyn-
thesis that is different in several steps from the isoprenoid pathway in the vertebrate host. The 
biosynthesis pathway is an important target for evaluating new antimalarial drugs and the 
terpenes for being derived from the isoprenoid pathway and having a similar structure can 
interfere in the synthesis of isoprenoids and should be evaluated as antimalarial potentials.
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